ImmunityBio, Inc. Files 8-K with Material Agreement
Ticker: IBRX · Form: 8-K · Filed: Apr 8, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
IBIO filed an 8-K on 4/7/25 for a material definitive agreement. Big news pending.
AI Summary
On April 7, 2025, ImmunityBio, Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 3530 John Hopkins Court, San Diego, California.
Why It Matters
This 8-K filing indicates a significant development for ImmunityBio, Inc., potentially involving a new contract or partnership that could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this initial filing warrants a medium risk assessment.
Key Players & Entities
- ImmunityBio, Inc. (company) — Registrant
- April 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 3530 John Hopkins Court, San Diego, California (address) — Principal executive offices
- NantKwest, Inc. (company) — Former company name
- Conkwest, Inc. (company) — Former company name
- ZelleRx Corp (company) — Former company name
FAQ
What is the nature of the material definitive agreement entered into by ImmunityBio, Inc. on April 7, 2025?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on April 7, 2025.
What are the primary business activities of ImmunityBio, Inc.?
ImmunityBio, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
When was ImmunityBio, Inc. previously known by other names?
ImmunityBio, Inc. was formerly known as NantKwest, Inc. (effective July 13, 2015), Conkwest, Inc. (effective April 16, 2014), and ZelleRx Corp (effective May 4, 2005).
Where are ImmunityBio, Inc.'s principal executive offices located?
The principal executive offices of ImmunityBio, Inc. are located at 3530 John Hopkins Court, San Diego, California, 92121.
What is the fiscal year end for ImmunityBio, Inc.?
The fiscal year end for ImmunityBio, Inc. is December 31 (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 8, 2025 regarding ImmunityBio, Inc. (IBRX).